Key Insights: Reaching Beyond Anti-TNFs in Moderate to Severe Ulcerative Colitis

Key Insights: Reaching Beyond Anti-TNFs in Moderate to Severe Ulcerative Colitis

On-Demand Webcast

Millie D. Long, MD, MPH, FACG
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Target Audience

This activity is intended for IBD specialists, gastroenterologists, nurses, nurse practitioners, and other healthcare professionals (internists, primary care physicians, physician assistants, pharmacists, etc) involved and/or interested in the therapeutic management of patients with IBD.


Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), causes inflammation of large intestine resulting in the formation of ulcers. An overactive immune system is thought to be one of the causes of UC. Depending on the severity of symptoms, a wide range of drugs including, antibiotics, corticosteroids, immunomodulators, and biologics are prescribed to treat UC. Janus kinase (JAK) molecules and immunologic pathways have been shown to play a major role in the inflammation of mucosal lining, leading to investigation of JAK inhibitors to treat UC.
In this Key Insights™ activity, Dr. Millie D. Long discusses the key take-home messages from the Reaching Beyond Anti-TNFs in Moderate to Severe UC symposium, held on December 13, 2018 during the 2018 Advances in Inflammatory Bowel Diseases conference in Orlando, Florida.


Upon successful completion of this educational activity, participants should be better able to:

  1. Discuss the benefits of a treat-to-target versus step-care approach to UC treatment with regards to disease progression and clinical outcomes
  2. Differentiate among newer and emerging classes of targeted therapies for UC in terms of their mechanisms of action and therapeutic potential
  3. Evaluate the pivotal clinical trial data surrounding the efficacy and safety of newer and emerging targeted therapies for UC
  4. Integrate the latest clinical data, FDA approvals, and guideline recommendations into individualized UC management plans

Release Date: December 21, 2018

Expiration Date: December 21, 2019

Hardware/Software Requirements

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to


Supported by an educational grant from Pfizer.


Imedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians.


In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Imedex. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Imedex designates this live educational activity for a maximum of 0.50 AMA PRA Category 1 Credit™.
Physicians should claim only credit commensurate with the extent of their participation in the activity.


NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 credit.

PAs should only claim credit commensurate with the extent of their participation.


This continuing nursing education activity awards 0.5 contact hour.


This knowledge-based activity (JA0006201-9999-18-245-H01-P/JA0006201-9999-19-113-H01-P) is approved for 0.5 contact hour (0.005 CEUs) of continuing pharmacy education.

ACPE Credit Policy

Your official record of ACPE credit will be generated through the CPE Monitor System. The certificate printed from this website after completing the evaluation for this activity is for personal tracking purposes only.

Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended. Please note that you must complete the activity evaluation within 60 days of a live activity or within 60 days of beginning the evaluation for an enduring activity. Under ACPE Policy, NACCME will not be able to report your activity completion to CPE Monitor after this 60-day period.

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact the Manager, Accreditation & Compliance, NACCME, in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation & Compliance will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Senior Director, Accreditation and Compliance, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Millie D. Long, MD, MPH, FACG, Miguel D. Regueiro, MD, FACG, Bruce E. Sands, MD, MS, FACG; and Chris Bolwell, Monalisa Singh, Manjusha Sala, and Susan Yarbrough, Imedex.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Imedex, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME and Imedex to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence. Faculty are instructed to provide a balanced view of therapeutic options by utilizing generic names to ensure impartiality.

All faculty are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

Millie D. Long, MD, MPH, FACG AbbVie2,3; Janssen2; Pfizer1,2; Takeda1,2; Target Pharmasolutions2; UCB2,3

All materials are included with the permission of the authors.

Chris Bolwell discloses that he holds shares of stock of GlaxoSmithKline.

Manjusha Sala and Susan Yarbrough disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

Disclosure of off-label/unapproved uses of drugs and/or devices will be provided prior to the symposium.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.